JP2005500012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500012A5 JP2005500012A5 JP2002569878A JP2002569878A JP2005500012A5 JP 2005500012 A5 JP2005500012 A5 JP 2005500012A5 JP 2002569878 A JP2002569878 A JP 2002569878A JP 2002569878 A JP2002569878 A JP 2002569878A JP 2005500012 A5 JP2005500012 A5 JP 2005500012A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- seq
- nuclear hormone
- hormone receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 20
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 17
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 17
- 108020001756 ligand binding domains Proteins 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 238000003745 diagnosis Methods 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 3
- 238000009739 binding Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000031295 Animal disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000031018 biological processes and functions Effects 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000017455 cell-cell adhesion Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105402.2A GB0105402D0 (en) | 2001-03-05 | 2001-03-05 | Novel proteins |
| PCT/GB2002/000948 WO2002070559A2 (en) | 2001-03-05 | 2002-03-05 | Nuclear hormone receptor ligand binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500012A JP2005500012A (ja) | 2005-01-06 |
| JP2005500012A5 true JP2005500012A5 (https=) | 2005-12-22 |
Family
ID=9909998
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569876A Pending JP2005500010A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
| JP2002570600A Pending JP2005500015A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
| JP2002569878A Pending JP2005500012A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569876A Pending JP2005500010A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
| JP2002570600A Pending JP2005500015A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040249132A1 (https=) |
| EP (3) | EP1373317A2 (https=) |
| JP (3) | JP2005500010A (https=) |
| AU (3) | AU2002234786A1 (https=) |
| CA (3) | CA2439205A1 (https=) |
| GB (1) | GB0105402D0 (https=) |
| WO (3) | WO2002070563A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070185017A1 (en) * | 2002-10-29 | 2007-08-09 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20070271619A1 (en) * | 2003-10-29 | 2007-11-22 | Heinz Von Der Kammer | Diagnostic and Therapeutic Use of the Human Dax-1 Gene and Protein for Neurodegenerative Diseases |
| WO2005100396A1 (en) * | 2004-04-16 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoid x receptor alpha (rxra) |
| EP4303232A3 (en) | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| JP7068169B2 (ja) | 2016-01-08 | 2022-05-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 条件付活性ヘテロ二量体ポリペプチド及びその使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712381A (en) * | 1994-10-19 | 1998-01-27 | Genetics Institute, Inc. | MADD, a TNF receptor death domain ligand protein |
| WO1998049276A1 (en) * | 1997-04-28 | 1998-11-05 | Helix Research Institute | Serine/threonine protein kinase |
| DE19816395A1 (de) * | 1998-04-03 | 1999-10-07 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Ovar-Normalgewebe |
-
2001
- 2001-03-05 GB GBGB0105402.2A patent/GB0105402D0/en not_active Ceased
-
2002
- 2002-03-05 JP JP2002569876A patent/JP2005500010A/ja active Pending
- 2002-03-05 US US10/469,866 patent/US20040249132A1/en not_active Abandoned
- 2002-03-05 JP JP2002570600A patent/JP2005500015A/ja active Pending
- 2002-03-05 JP JP2002569878A patent/JP2005500012A/ja active Pending
- 2002-03-05 EP EP02703738A patent/EP1373317A2/en not_active Withdrawn
- 2002-03-05 AU AU2002234786A patent/AU2002234786A1/en not_active Abandoned
- 2002-03-05 EP EP02703732A patent/EP1373315A2/en not_active Withdrawn
- 2002-03-05 CA CA002439205A patent/CA2439205A1/en not_active Abandoned
- 2002-03-05 WO PCT/GB2002/000986 patent/WO2002070563A2/en not_active Ceased
- 2002-03-05 EP EP02701458A patent/EP1370584A2/en not_active Withdrawn
- 2002-03-05 AU AU2002237421A patent/AU2002237421A1/en not_active Abandoned
- 2002-03-05 WO PCT/GB2002/000948 patent/WO2002070559A2/en not_active Ceased
- 2002-03-05 CA CA002439192A patent/CA2439192A1/en not_active Abandoned
- 2002-03-05 CA CA002439196A patent/CA2439196A1/en not_active Abandoned
- 2002-03-05 WO PCT/GB2002/000937 patent/WO2002070557A2/en not_active Ceased
- 2002-03-05 US US10/469,865 patent/US20040249123A1/en not_active Abandoned
- 2002-03-05 AU AU2002237415A patent/AU2002237415A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walter et al. | Molecular cloning and sequence of cDNA encoding polyoma medium tumor antigen-associated 61-kDa protein. | |
| JP2015530390A5 (https=) | ||
| JP2002508970A5 (https=) | ||
| JP2008536483A5 (https=) | ||
| JP2002508183A5 (https=) | ||
| JP2006502702A5 (https=) | ||
| JP2005502319A5 (https=) | ||
| JP2005500012A5 (https=) | ||
| JP2005500015A5 (https=) | ||
| JP2005500010A5 (https=) | ||
| Liu et al. | Preparation of β2-homologous amino acids bearing polar side chains via a collective synthesis strategy | |
| JP2005528086A5 (https=) | ||
| JP2005528083A5 (https=) | ||
| JP2004535161A5 (https=) | ||
| JP2008517605A5 (https=) | ||
| Hu et al. | (4-Piperidin-1-yl) phenyl amides: potent and selective human β3 agonists | |
| JP2005500013A5 (https=) | ||
| JP2008517616A5 (https=) | ||
| JP2007536910A5 (https=) | ||
| JP2005500014A5 (https=) | ||
| Liebler et al. | From IHF protein to design and synthesis of a sequence-specific DNA bending peptide | |
| JP2005500820A5 (https=) | ||
| JP2005500011A5 (https=) | ||
| JP4150201B2 (ja) | 遺伝子チップの調製方法 | |
| CN110862434B (zh) | 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用 |